{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T16:27:24Z","timestamp":1793636844729,"version":"4.5.1"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004735","name":"Hunan Provincial Natural Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.bcp.2026.118560","type":"journal-article","created":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T23:06:37Z","timestamp":1792537597000},"page":"118560","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"P4","title":["Characterization of F-30 as an FGFR2\/4-selective covalent inhibitor with activity against clinically relevant mutations"],"prefix":"10.1016","volume":"254","author":[{"given":"Lin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueru","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wuqing","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanyuxuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Gui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuepiao","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2026.118560_b0005","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/s41571-024-00869-z","article-title":"FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions","volume":"21","author":"Katoh","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bcp.2026.118560_b0010","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/s41573-024-01125-w","article-title":"FGF-based drug discovery: advances and challenges","volume":"24","author":"Chen","year":"2025","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bcp.2026.118560_b0015","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13045-024-01558-1","article-title":"Targeting FGFR for cancer therapy","volume":"17","author":"Zhang","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bcp.2026.118560_b0020","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13045-021-01040-2","article-title":"FGFR-TKI resistance in cancer: current status and perspectives","volume":"14","author":"Yue","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bcp.2026.118560_b0025","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.3390\/biomedicines12051117","article-title":"Clinical developments and challenges in treating FGFR2-driven gastric cancer","volume":"12","author":"Lau","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.bcp.2026.118560_b0030","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1146\/annurev-med-042921-024707","article-title":"FGFR2 Inhibition in Cholangiocarcinoma","volume":"74","author":"Vogel","year":"2023","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.bcp.2026.118560_b0035","doi-asserted-by":"crossref","first-page":"e1223","DOI":"10.1002\/ctm2.1223","article-title":"FGFR2 mutations promote endometrial cancer progression through dual engagement of EGFR and Notch signalling pathways","volume":"13","author":"Dixit","year":"2023","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.bcp.2026.118560_b0040","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.jhep.2021.07.029","article-title":"Dark and bright side of targeting fibroblast growth factor receptor 4 in the liver","volume":"75","author":"Gadaleta","year":"2021","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bcp.2026.118560_b0045","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/joim.13767","article-title":"Targeting the FGF19-FGFR4 pathway for cholestatic, metabolic, and cancerous diseases","volume":"295","author":"Li","year":"2024","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.bcp.2026.118560_b0050","doi-asserted-by":"crossref","first-page":"614","DOI":"10.3390\/cells8060614","article-title":"Fibroblast growth factor receptors (FGFRs): structures and small molecule inhibitors","volume":"8","author":"Dai","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.bcp.2026.118560_b0055","article-title":"Clinical development and management of adverse events associated with FGFR inhibitors","volume":"4","author":"Subbiah","year":"2023","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.bcp.2026.118560_b0060","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1158\/2159-8290.CD-19-0182","article-title":"TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion\u2013positive intrahepatic cholangiocarcinoma","volume":"9","author":"Goyal","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bcp.2026.118560_b0065","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1158\/2159-8290.CD-16-1000","article-title":"Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive cholangiocarcinoma","volume":"7","author":"Goyal","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bcp.2026.118560_b0070","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.annonc.2024.12.011","article-title":"A model for decoding resistance in precision oncology: acquired resistance to FGFR inhibitors in cholangiocarcinoma","volume":"36","author":"Goyal","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bcp.2026.118560_b0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ctrv.2019.06.003","article-title":"FGFR2 genomic aberrations: achilles heel in the management of advanced cholangiocarcinoma","volume":"78","author":"Mahipal","year":"2019","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.bcp.2026.118560_b0080","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1021\/acs.jmedchem.1c01719","article-title":"Discovery of cysteine-targeting covalent protein kinase inhibitors","volume":"65","author":"Lu","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2026.118560_b0085","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/cmdc.201800719","article-title":"TAS-120 cancer target binding: defining reactivity and revealing the first fibroblast growth factor receptor 1 (FGFR1) irreversible structure","volume":"14","author":"Kalyukina","year":"2019","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bcp.2026.118560_b0090","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1158\/1535-7163.MCT-17-0309","article-title":"The irreversible covalent fibroblast growth factor receptor inhibitor PRN1371 exhibits sustained inhibition of FGFR after drug clearance","volume":"16","author":"Venetsanakos","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bcp.2026.118560_b0095","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1158\/2159-8290.CD-23-0475","article-title":"RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations","volume":"13","author":"Subbiah","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bcp.2026.118560_b0100","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2317756121","article-title":"Discovery of lirafugratinib (RLY-4008), a highly selective irreversible small-molecule inhibitor of FGFR2","volume":"121","author":"Sch\u00f6nherr","year":"2024","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bcp.2026.118560_b0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117339","article-title":"Discovery of BW710 as a potent, selective and orally bioavailable fibroblast growth factor receptor 2 (FGFR2) inhibitor","volume":"287","author":"Yang","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bcp.2026.118560_b0110","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1158\/2159-8290.CD-14-1029","article-title":"First selective small molecule inhibitor of FGFR4 for the treatment of hepatocellular carcinomas with an activated FGFR4 signaling pathway","volume":"5","author":"Hagel","year":"2015","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bcp.2026.118560_b0115","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1021\/acsmedchemlett.9b00196","article-title":"Rotational freedom, steric hindrance, and protein dynamics explain BLU554 selectivity for the hinge cysteine of FGFR4","volume":"10","author":"Lin","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bcp.2026.118560_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116281","article-title":"Design, synthesis, and biological evaluation of selective covalent inhibitors of FGFR4","volume":"268","author":"Chen","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bcp.2026.118560_b0125","doi-asserted-by":"crossref","first-page":"12542","DOI":"10.1021\/acs.jmedchem.0c01019","article-title":"Discovery of Roblitinib (FGF401) as a reversible-covalent inhibitor of the kinase activity of fibroblast growth factor receptor 4","volume":"63","author":"Fairhurst","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2026.118560_b0130","doi-asserted-by":"crossref","first-page":"5890","DOI":"10.1039\/C9CC02052G","article-title":"Characterization of FGF401 as a reversible covalent inhibitor of fibroblast growth factor receptor 4","volume":"55","author":"Zhou","year":"2019","journal-title":"Chem. Commun."},{"key":"10.1016\/j.bcp.2026.118560_b0135","doi-asserted-by":"crossref","first-page":"14809","DOI":"10.1021\/acs.jmedchem.2c01319","article-title":"Design, synthesis, and biological evaluation of 5-Formyl-pyrrolo[3,2-b]pyridine-3-carboxamides as new selective, potent, and reversible-covalent FGFR4 inhibitors","volume":"65","author":"Yang","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2026.118560_b0140","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s42004-022-00657-9","article-title":"Structure-based design of a dual-warhead covalent inhibitor of FGFR4","volume":"5","author":"Chen","year":"2022","journal-title":"Commun. Chem."},{"key":"10.1016\/j.bcp.2026.118560_b0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113219","article-title":"Design, synthesis, and biological evaluation of indazole derivatives as selective and potent FGFR4 inhibitors for the treatment of FGF19-driven hepatocellular cancer","volume":"214","author":"Chen","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bcp.2026.118560_b0150","doi-asserted-by":"crossref","first-page":"12089","DOI":"10.1039\/C8CC07546H","article-title":"LY2874455 potently inhibits FGFR gatekeeper mutants and overcomes mutation-based resistance","volume":"54","author":"Wu","year":"2018","journal-title":"Chem. Commun."},{"key":"10.1016\/j.bcp.2026.118560_b0155","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1107\/S0907444906019949","article-title":"HKL-3000: the integration of data reduction and structure solution\u2013from diffraction images to an initial model in minutes, Acta crystallographica Section D","volume":"62","author":"Minor","year":"2006","journal-title":"Biol. Crystall."},{"key":"10.1016\/j.bcp.2026.118560_b0160","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1107\/S1600577524011597","article-title":"Status of macromolecular crystallography beamlines at SSRF","volume":"32","author":"Kong","year":"2025","journal-title":"J. Synchrotron Rad."},{"key":"10.1016\/j.bcp.2026.118560_b0165","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1107\/S1600576724002188","article-title":"Upgrade of crystallography beamline BL19U1 at the Shanghai synchrotron radiation facility","volume":"57","author":"Xiao","year":"2024","journal-title":"J. Appl. Crystallogr."},{"key":"10.1016\/j.bcp.2026.118560_b0170","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1107\/S2059798319011471","article-title":"Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix","volume":"75","author":"Liebschner","year":"2019","journal-title":"Acta Crystallogr. D Struct. Biol."},{"key":"10.1016\/j.bcp.2026.118560_b0175","doi-asserted-by":"crossref","first-page":"7473","DOI":"10.1021\/acs.jmedchem.9b00510","article-title":"Discovery and development of a series of Pyrazolo[3,4-d]pyridazinone compounds as the novel covalent fibroblast growth factor receptor inhibitors by the rational drug design","volume":"62","author":"Wang","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2026.118560_b0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115453","article-title":"Structure-based drug design of 1,3,5-triazine and pyrimidine derivatives as novel FGFR3 inhibitors with high selectivity over VEGFR2","volume":"28","author":"Kuriwaki","year":"2020","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bcp.2026.118560_b0185","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1002\/pro.3791","article-title":"Current developments in coot for macromolecular model building of electron cryo-microscopy and crystallographic data","volume":"29","author":"Casa\u00f1al","year":"2020","journal-title":"Protein Sci."},{"key":"10.1016\/j.bcp.2026.118560_b0190","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1021\/ci500118s","article-title":"Docking covalent inhibitors: a parameter free approach to pose prediction and scoring","volume":"54","author":"Zhu","year":"2014","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.bcp.2026.118560_b0195","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s42004-021-00623-x","article-title":"Structural insights into the potency and selectivity of covalent pan-FGFR inhibitors","volume":"5","author":"Qu","year":"2022","journal-title":"Commun. Chem."},{"key":"10.1016\/j.bcp.2026.118560_b0200","article-title":"Targeting wild-type and mutationally activated FGFR4 in rhabdomyosarcoma with the inhibitor ponatinib (AP24534)","volume":"8","author":"Li","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2026.118560_b0205","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.21137","article-title":"Elucidation of a four-site allosteric network in fibroblast growth factor receptor tyrosine kinases","volume":"6","author":"Chen","year":"2017","journal-title":"Elife"},{"key":"10.1016\/j.bcp.2026.118560_b0210","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.molcel.2007.06.028","article-title":"A molecular brake in the kinase hinge region regulates the activity of receptor tyrosine kinases","volume":"27","author":"Chen","year":"2007","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bcp.2026.118560_b0215","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1016\/j.str.2014.09.019","article-title":"Structural insights into FGFR kinase isoform selectivity: diverse binding modes of AZD4547 and Ponatinib in complex with FGFR1 and FGFR4","volume":"22","author":"Tucker","year":"2014","journal-title":"Structure"},{"key":"10.1016\/j.bcp.2026.118560_b0220","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1158\/2159-8290.CD-19-0555","article-title":"First-in-human phase I study of Fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular Carcinoma","volume":"9","author":"Kim","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bcp.2026.118560_b0225","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/s42004-022-00718-z","article-title":"Characterization of the cholangiocarcinoma drug pemigatinib against FGFR gatekeeper mutants","volume":"5","author":"Lin","year":"2022","journal-title":"Commun. Chem."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226009032?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226009032?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T15:43:24Z","timestamp":1793634204000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295226009032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":45,"alternative-id":["S0006295226009032"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118560","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterization of F-30 as an FGFR2\/4-selective covalent inhibitor with activity against clinically relevant mutations","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118560","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118560"}}